H. Lundbeck HLUN-B.CO
DenmarkHealthcare · Drug Manufacturers - Specialty & GenericNasdaq Copenhague · DKK
49.19 DKK (+9.1%)
13 analysts
XTB1.00 €affiliateOpen account ↗
Interactive Brokers4.74 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗Interactive Brokers4.74 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
H. Lundbeck is a Danish pharmaceutical company specializing in the development and commercialization of drugs for central nervous system disorders, such as depression, schizophrenia and Alzheimer's disease.
Listed on Nasdaq Copenhague · Symbol HLUN-B.CO · CPH: HLUN-B · Currency DKK
Key points
from its scores- ✓Favourable backdrop9.3
- ✓High-quality business7.7
- ✓Attractive valuation7.5
- ✕Poor share-price trend4.0
AI analysis
bottom line, main risk, context and newsThe combination of low valuation, moat from gross margin and earnings growth makes it attractive for long-term profiles.
Lundbeck presents solid fundamentals: attractive valuation (P/E 11.50, FCF yield 13.30%), gross margin of 82.06% and controlled debt (ND/EBITDA 0.87), with earnings growth of 22.10% supporting the investment thesis.
The main risk is regulatory pressure on drug pricing in its key markets (US and Europe), which could compress future margins despite the current gross margin of 82.06%.
Context and risks
Lundbeck has no material exposure to current macro factors: its pharmaceutical business does not depend on interest rates (net debt/EBITDA of 0.87), oil, or shipping routes. The main risk is specific to its sector: regulatory pressure on drug pricing and dependence on the pipeline, which are not affected by the macro context.
Is H. Lundbeck stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 57% below the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 11.5 | 26.7 | −57% |
| EV / EBITDA | 6.3 | 14.5 | −57% |
| Price / book | 1.7 | 4.1 | −60% |
| Price / sales | 1.7 | 3.4 | −50% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 7.5 out of 10 (median for Healthcare: 4.7).
Average analyst target: 49.19 DKK, +9.1% versus the price.
A discount may reflect more risk or slower growth than its sector: Financial health 7.4 (sector 6.5), Growth 6.9 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 11.5
- Forward P/E
- 7.3
- EV / EBITDA
- 6.3
- Price / book
- 1.7
- Price / sales
- 1.7
- PEG
- 8.05
- Market cap
- 44.7B DKK
- Enterprise value
- 51.8B DKK
Profitability
- ROE
- 15.4%
- ROA
- 7.8%
- ROIC (approx.)
- 16.6%
- Gross margin
- 82.1%
- Operating margin
- 23.2%
- Net margin
- 15.2%
- Free cash flow
- 5.9B DKK
- FCF yield
- 13.3%
- Cash conversion
- 72%
Solvency
- Total debt
- 9.4B DKK
- Net debt
- 7.2B DKK
- Cash
- 2.2B DKK
- EBITDA
- 8.3B DKK
- Net debt / EBITDA
- 0.87
- Debt / equity
- 35.05
- Current ratio
- 1.37
- Quick ratio
- 0.90
Growth
- Revenue growth
- +7.3%
- Earnings growth
- +22.1%
- EPS (TTM)
- 3.92 DKK
- EPS (forward)
- 6.19 DKK
Dividend
- Dividend yield
- 2.6%
- Payout
- 29.3%
Risk and market
- Beta
- 0.24
- Analyst consensus
- Buy (13)
- Target price
- 49.19 DKK
- 52-week range
- 35.30 – 47.78
Recent news
All HLUN-B.CO news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about H. Lundbeck
Is H. Lundbeck stock cheap or expensive?
On P/E and EV / EBITDA, it trades 57% below the Healthcare median on average. Valuation score: 7.5 out of 10 (median for Healthcare: 4.7). Average analyst target: 49.19 DKK, +9.1% versus the price. This is not investment advice.
What score does H. Lundbeck get on MeridIAn Screener?
It scores 7.4 out of 10, rank 66 of 2,130 (better than 97% of the companies analysed). Its strongest category is Risk & Context (9.3) and its weakest, Momentum (4.0). Analysis of 08/10/2026.
What is H. Lundbeck's P/E ratio?
Its P/E is 11.5: the share price equals 11.5 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 7.3.
How much is H. Lundbeck worth on the stock market?
Its market capitalisation is 44.7B DKK and its enterprise value, debt included, is 51.8B DKK.
How much debt does H. Lundbeck have?
Its net debt (debt minus cash) is 7.2B DKK. That is 0.87 times its EBITDA; the Healthcare median is 1.53.
Does H. Lundbeck pay a dividend?
Yes: its dividend yield is 2.55% and it pays out 29% of its earnings.
How has H. Lundbeck stock performed over the last year?
It has risen 1.3% over the last year, excluding dividends. Over the last 52 weeks it has traded between 35.30 and 47.78 DKK. Past performance does not guarantee future results.
What do analysts think of H. Lundbeck?
13 analysts cover it; their average recommendation is “Buy” and their average target is 49.19 DKK (+9.1% versus the price). It is an estimate, not market data.